W. K. De-jong, J. L. Blaauwgeers, M. Schaapveld, W. Timens, T. J. Klinkenberg et al., Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy, Eur J Cancer, vol.44, issue.1, pp.123-153, 2008.

A. Marx, P. Strobel, S. S. Badve, L. Chalabreysse, J. K. Chan et al., ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting, J Thorac Oncol, vol.9, issue.5, pp.596-611, 2014.

N. Girard, E. Ruffini, A. Marx, C. Faivre-finn, S. Peters et al., Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.40-55, 2015.

A. Masaoka, Y. Monden, K. Nakahara, and T. Tanioka, Follow-up study of thymomas with special reference to their clinical stages, Cancer, vol.48, issue.11, pp.2485-92, 1981.

G. Chen, A. Marx, W. H. Chen, J. Yong, B. Puppe et al., New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China, Cancer, vol.95, issue.2, pp.420-429, 2002.

J. F. Regnard, P. Magdeleinat, C. Dromer, E. Dulmet, V. De-montpreville et al., Prognostic factors and long-term results after thymoma resection: a series of 307 patients, J Thorac Cardiovasc Surg, vol.112, issue.2, p.8751506, 1996.

N. Safieddine, G. Liu, K. Cuningham, T. Ming, D. Hwang et al., Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma, J Thorac Oncol, vol.9, issue.7, pp.1018-1040, 2014.

A. Berruti, P. Borasio, A. Gerbino, G. Gorzegno, T. Moschini et al., Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single

N. Girard, R. Lal, H. Wakelee, G. J. Riely, and P. J. Loehrer, Chemotherapy definitions and policies for thymic malignancies, J Thorac Oncol, vol.6, issue.7, pp.1749-55, 2011.

P. J. Loehrer, . Sr, M. Chen, K. Kim, S. C. Aisner et al., Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial, J Clin Oncol, vol.15, issue.9, pp.3093-3102, 1997.

N. Girard, M. Du-vignaux, and C. , How large databases may impact clinical practices for rare tumorspostoperative chemotherapy in thymic malignancies, Journal of thoracic disease, vol.8, issue.8, pp.1863-1867, 2016.

G. L. Lemma, J. W. Lee, S. C. Aisner, C. J. Langer, W. J. Tester et al., Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma, J Clin Oncol, vol.29, issue.15, pp.2060-2065, 2011.

P. J. Loehrer, . Sr, K. Kim, S. C. Aisner, R. Livingston et al., Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group

, J Clin Oncol, vol.12, issue.6, pp.1164-1172, 1994.

P. J. Loehrer, . Sr, W. Wang, D. H. Johnson, S. C. Aisner et al., Eastern Cooperative Oncology Group Phase IIT. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial, J Clin Oncol, vol.22, issue.2, pp.293-302, 2004.

G. Palmieri, M. Marino, C. Buonerba, P. Federico, S. Conti et al., Imatinib mesylate in thymic epithelial malignancies, Cancer Chemother Pharmacol, vol.69, issue.2, pp.309-324, 2012.

Y. Wang, A. Thomas, C. Lau, A. Rajan, Y. Zhu et al., Mutations of epigenetic regulatory genes are common in thymic carcinomas, Scientific reports, vol.4, p.7336, 2014.

A. L. Moreira, H. H. Won, R. Mcmillan, J. Huang, G. J. Riely et al., Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis, J Thorac Oncol, vol.10, issue.2, pp.373-80, 2015.

K. M. Druey, Bridging with GAPs: receptor communication through RGS proteins. Science's STKE: signal transduction knowledge environment, p.14, 2001.

A. Hirano, M. Emi, M. Tsuneizumi, Y. Utada, M. Yoshimoto et al., Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer, Clin Cancer Res, vol.7, issue.4, pp.876-82, 2001.

R. Penzel, J. Hoegel, W. Schmitz, H. Blaeker, A. Morresi-hauf et al., Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka, Int J Cancer, vol.105, issue.4, pp.494-502, 2003.

P. Starostik, A. Greiner, A. Schultz, A. Zettl, K. Peters et al., Genetic aberrations common in gastric high-grade large B-cell lymphoma, Blood, vol.95, issue.4, pp.1180-1187, 2000.

T. Khoury, A. Arshad, P. Bogner, N. Ramnath, S. Zhang et al., Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms, Chest, vol.136, issue.1, pp.220-228, 2009.

I. Petrini, P. S. Meltzer, P. A. Zucali, J. Luo, C. Lee et al., Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors, Cell death & disease, vol.3, p.351, 2012.

A. T. Alberobello, Y. Wang, F. J. Beerkens, F. Conforti, J. N. Mccutcheon et al., PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors, J Thorac Oncol, vol.11, issue.8, pp.1345-56, 2016.

M. Kossai, B. Duchemann, C. Boutros, C. Caramella, A. Hollebecque et al., Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer, vol.89, pp.306-316, 2015.

P. A. Zucali, T. De-pas, G. Palmieri, A. Favaretto, A. Chella et al., Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy, J Clin Oncol, vol.36, issue.4, pp.342-351, 2018.

J. Wheler, D. Hong, S. G. Swisher, G. Falchook, A. M. Tsimberidou et al., Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses, Oncotarget, vol.4, issue.6, pp.890-898, 2013.

M. Scorsetti, F. Leo, A. Trama, D. 'angelillo, R. Serpico et al., Thymoma and thymic carcinomas, Crit Rev Oncol Hematol, vol.99, pp.332-50, 2016.

I. Dagogo-jack and A. T. Shaw, Crizotinib resistance: implications for therapeutic strategies, Ann Oncol, vol.27, issue.3, pp.42-50, 2016.

N. Girard, R. Shen, T. Guo, M. F. Zakowski, A. Heguy et al., Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas, Clin Cancer Res, vol.15, issue.22, pp.6790-6799, 2009.

P. A. Zucali, D. Tommaso, L. Petrini, I. Battista, S. Lee et al., Reproducibility of the WHO classification of thymomas: practical implications, Lung Cancer, vol.79, issue.3, pp.236-277, 2013.

M. Breinig, P. Mayer, A. Harjung, B. Goeppert, M. Malz et al., Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors, Clin Cancer Res, vol.17, issue.8, pp.2237-2286, 2011.

A. Rajan, C. A. Carter, A. Berman, L. Cao, R. J. Kelly et al., Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The lancet oncology, vol.15, pp.191-200, 2014.

P. A. Zucali, T. De-pas, G. Palmieri, A. Favaretto, A. Chella et al., Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy, J Clin Oncol, p.2017744078, 2017.

Y. Gokmen-polar, K. L. Sanders, C. P. Goswami, O. D. Cano, N. A. Zaheer et al., Establishment and characterization of a novel cell line derived from human thymoma AB tumor, Lab Invest, vol.92, issue.11, pp.1564-73, 2012.

L. C. Kim, R. S. Cook, and J. Chen, mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene, vol.36, pp.2191-201, 2017.

N. Girard, Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?, J Thorac Oncol, vol.11, issue.8, pp.1197-200, 2016.

M. Radovich, J. P. Solzak, B. A. Hancock, M. L. Conces, R. Atale et al., A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas, Br J Cancer, vol.114, issue.4, pp.477-84, 2016.

M. Radovich, C. R. Pickering, I. Felau, G. Ha, H. Zhang et al., The Integrated Genomic Landscape of Thymic Epithelial Tumors, Cancer cell, vol.33, issue.2, pp.244-58, 2018.